Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa

Gary L. Clayman; Frank J. Liu; Howard E. Savage; Dorothy L. Taylor; Pierre Lavedan; Robert M. Buchsbaum; Candice Pellegrino; Jose M. Trujillo; Gregory Young; Stimson P. Schantz

doi:10.1001/archotol.1992.01880010045014

Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa

Gary L. Clayman, Frank J. Liu, Howard E. Savage, Dorothy L. Taylor, Pierre Lavedan, Robert M. Buchsbaum, Candice Pellegrino, Jose M. Trujillo, Gregory Young, Stimson P. Schantz

Head & Neck Surgery

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Circulating acute-phase proteins may mediate adverse reactions in patients receiving biologic response modifiers, including inhibition of immune responsiveness and clinical toxic effects. Nine patients with unresectable head and neck squamous cell carcinoma were prospectively examined for levels of acute-phase proteins during interleukin 2/interferon alfa immunotherapy and for clinical toxic effects. Simultaneous determination of the in vitro immunomodulatory capacity of autologous serum on the induction of lymphokine-activated killer cells was assessed in 4-hour chromium release assays. Of the seven acute-phase proteins analyzed, haptoglobin and C-reactive protein levels were elevated before therapy was started. Toxic events leading to cessation of interleukin 2/interferon alfa therapy had a high correlation with elevated C-reactive protein and lowered C3 component of complement levels. No relationship was noted between serum levels of acute-phase proteins and induction inhibition of lymphokine-activated killer cell cytotoxicity. The role of C-reactive protein and complement degradation products in mediating interleukin 2/interferon alfa toxicity requires further investigation.

Original language	English (US)
Pages (from-to)	41-48
Number of pages	8
Journal	Archives of Otolaryngology--Head and Neck Surgery
Volume	118
Issue number	1
DOIs	https://doi.org/10.1001/archotol.1992.01880010045014
State	Published - Jan 1992

ASJC Scopus subject areas

Surgery
Otorhinolaryngology

Access to Document

10.1001/archotol.1992.01880010045014

Cite this

Clayman, G. L., Liu, F. J., Savage, H. E., Taylor, D. L., Lavedan, P., Buchsbaum, R. M., Pellegrino, C., Trujillo, J. M., Young, G., & Schantz, S. P. (1992). Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa. Archives of Otolaryngology--Head and Neck Surgery, 118(1), 41-48. https://doi.org/10.1001/archotol.1992.01880010045014

@article{e7d6d20b84f244eebb11620c20abda54,

title = "Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa",

abstract = "Circulating acute-phase proteins may mediate adverse reactions in patients receiving biologic response modifiers, including inhibition of immune responsiveness and clinical toxic effects. Nine patients with unresectable head and neck squamous cell carcinoma were prospectively examined for levels of acute-phase proteins during interleukin 2/interferon alfa immunotherapy and for clinical toxic effects. Simultaneous determination of the in vitro immunomodulatory capacity of autologous serum on the induction of lymphokine-activated killer cells was assessed in 4-hour chromium release assays. Of the seven acute-phase proteins analyzed, haptoglobin and C-reactive protein levels were elevated before therapy was started. Toxic events leading to cessation of interleukin 2/interferon alfa therapy had a high correlation with elevated C-reactive protein and lowered C3 component of complement levels. No relationship was noted between serum levels of acute-phase proteins and induction inhibition of lymphokine-activated killer cell cytotoxicity. The role of C-reactive protein and complement degradation products in mediating interleukin 2/interferon alfa toxicity requires further investigation.",

author = "Clayman, {Gary L.} and Liu, {Frank J.} and Savage, {Howard E.} and Taylor, {Dorothy L.} and Pierre Lavedan and Buchsbaum, {Robert M.} and Candice Pellegrino and Trujillo, {Jose M.} and Gregory Young and Schantz, {Stimson P.}",

year = "1992",

month = jan,

doi = "10.1001/archotol.1992.01880010045014",

language = "English (US)",

volume = "118",

pages = "41--48",

journal = "Archives of Otolaryngology--Head and Neck Surgery",

issn = "0886-4470",

publisher = "American Medical Association",

number = "1",

}

TY - JOUR

T1 - Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa

AU - Clayman, Gary L.

AU - Liu, Frank J.

AU - Savage, Howard E.

AU - Taylor, Dorothy L.

AU - Lavedan, Pierre

AU - Buchsbaum, Robert M.

AU - Pellegrino, Candice

AU - Trujillo, Jose M.

AU - Young, Gregory

AU - Schantz, Stimson P.

PY - 1992/1

Y1 - 1992/1

N2 - Circulating acute-phase proteins may mediate adverse reactions in patients receiving biologic response modifiers, including inhibition of immune responsiveness and clinical toxic effects. Nine patients with unresectable head and neck squamous cell carcinoma were prospectively examined for levels of acute-phase proteins during interleukin 2/interferon alfa immunotherapy and for clinical toxic effects. Simultaneous determination of the in vitro immunomodulatory capacity of autologous serum on the induction of lymphokine-activated killer cells was assessed in 4-hour chromium release assays. Of the seven acute-phase proteins analyzed, haptoglobin and C-reactive protein levels were elevated before therapy was started. Toxic events leading to cessation of interleukin 2/interferon alfa therapy had a high correlation with elevated C-reactive protein and lowered C3 component of complement levels. No relationship was noted between serum levels of acute-phase proteins and induction inhibition of lymphokine-activated killer cell cytotoxicity. The role of C-reactive protein and complement degradation products in mediating interleukin 2/interferon alfa toxicity requires further investigation.

AB - Circulating acute-phase proteins may mediate adverse reactions in patients receiving biologic response modifiers, including inhibition of immune responsiveness and clinical toxic effects. Nine patients with unresectable head and neck squamous cell carcinoma were prospectively examined for levels of acute-phase proteins during interleukin 2/interferon alfa immunotherapy and for clinical toxic effects. Simultaneous determination of the in vitro immunomodulatory capacity of autologous serum on the induction of lymphokine-activated killer cells was assessed in 4-hour chromium release assays. Of the seven acute-phase proteins analyzed, haptoglobin and C-reactive protein levels were elevated before therapy was started. Toxic events leading to cessation of interleukin 2/interferon alfa therapy had a high correlation with elevated C-reactive protein and lowered C3 component of complement levels. No relationship was noted between serum levels of acute-phase proteins and induction inhibition of lymphokine-activated killer cell cytotoxicity. The role of C-reactive protein and complement degradation products in mediating interleukin 2/interferon alfa toxicity requires further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0026528991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026528991&partnerID=8YFLogxK

U2 - 10.1001/archotol.1992.01880010045014

DO - 10.1001/archotol.1992.01880010045014

M3 - Article

C2 - 1370199

AN - SCOPUS:0026528991

SN - 0886-4470

VL - 118

SP - 41

EP - 48

JO - Archives of Otolaryngology--Head and Neck Surgery

JF - Archives of Otolaryngology--Head and Neck Surgery

IS - 1

ER -

Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this